KPI’s November 2022: Patients in RPM as of November 30, 2022: 3,100 Annual revenue rate as of November 30, 2022: 3.2 MUSD Explanations of KPI’sPatients in RPM as of November 30, 2022 – Number of patients that the company monitors in USA at the end of November.Annual revenue rate as of November 30, 2022 –…
Coala Life announces today that the company has decided to expand its service for Managed RPM in the USA from December 15, 2022. In the extended service, a more comprehensive analysis and reporting is provided to the care provider. When fully implemented, the expanded service will mean that the revenue per patient increases by about…
20% lower costs per SEK sold from Q2 2023 Managed RPM in the US drives growth Coala Life announces that the company confirms its communicated financial goals, to reach positive cash flow and positive EBITDA no later than 2024. Furthermore, it is estimated that the company’s costs per SEK sold, i.e. in relation to turnover,…
Coala Life's CEO, Dan Pitulia, acquired 300,000 shares on August 23, 2022 at a total value of approximately 0,64 MSEK, with an average price per share of 2.13 SEK. The shares were acquired on Nasdaq First North Growth Market. Following the acquisition, Dan Pitulia owns a total of 3,811,279 shares, corresponding to 4.80 percent of…
Investors, analysts and journalists are invited to watch an interview with CEO Dan Pitulia that covers the acquisition of Vitrics and the Q2 report, led by Jessica Grunewald, analyst at Redeye. The interview can be viewed via the following link:https://redeye-3.wistia.com/medias/mnm4dyu7lq About us Coala Life is a medical device company founded in Sweden focusing on cloud-based…
The due diligence process and the acquisition were estimated to be completed by July 31, 2022. New estimated completion date of the due diligence process and the deal is August 14, 2022. Coala Life announced via a press release on June 9, 2022 that the company has entered into an agreement to acquire 100 percent…
Correction refers to reference to incorrect date changed in this press release: CEO buys shares in Coala-Life Group AB (publ) Coala Life's CEO, Dan Pitulia, acquired 100,000 shares on July 15, 2022 at a total value of approximately 0,245 MSEK, with an average price per share of 2,4550 SEK. The shares were acquired on Nasdaq…
Coala Life's CEO, Dan Pitulia, acquired 100,000 shares on June 15, 2022 at a total value of approximately 0,245 MSEK, with an average price per share of 2,4550 SEK. The shares were acquired on Nasdaq First North Growth Market. Following the acquisition, Dan Pitulia owns a total of 3,511,279 shares, corresponding to 4.42 percent of…
We encourage everyone to visit and explore the website! https://www.coalalife.com/en/ Our goal with this new website is to create a more user-friendly experience and give our visitors an easy way to discover more about our services and the solutions we can offer. A more modern look, simplified navigation, responsive layout for smartphone users, and more…
Coala Life’s CEO, Dan Pitulia, acquired 500,000 shares on June 9, 2022 at a total value of approximately 1,6 MSEK, with an average price per share of 3.2277 SEK. The shares were acquired on Nasdaq First North Growth Market.
On May 24, 2022, Coala Life will publish its report for the first quarter of 2022. On the same day at 09.00 CEST, investors, analysts and journalists are invited to a webcast where CEO Dan Pitulia presents the report and latest updates from the market followed by a question-and-answer session led by Erik Nordström, analyst…
The Swedish Medical Technology Product Council (MTP) recommends the use of Coala Heart Monitor in all Swedish regional councils for assessment and diagnostics of patients with suspected atrial fibrillation. The recommendation is based on an overall assessment of clinical relevance, cost-effectiveness, and data security.
In connection with the listing on First North 2021, Coala Life announced financial targets to reach sales of SEK 250 million in 2024 with a positive operating profit. The majority of revenues were expected to be generated in the US market with a gross margin in excess of 80%. The financial objectives were based on…
On March 16 at 1.50pm, Dan Pitulia, CEO of Coala Life will present the latest developments in the company at Redeye. The presentation is live broadcasted and can be followed at https://us02web.zoom.us/j/86991641341?pwd=WGx2V0c1aXkvbVhBQTdhdWhESGZiUT09 where the replay and the presentations will be available afterwards. About us Coala Life is a medical device company founded in Sweden focusing…
The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has, at the request of the Medical Technology Product Council (MTP), carried out a Health economic analysis of Coala Heart Monitor Pro for remote monitoring and diagnosis of atrial fibrillation. The results have now been published by TLV with the conclusion that…
Coala-Life Group AB (publ), a leading company in cloud-based remote monitoring of heart and lung diseases, today announces the appointment of Johan Eckerdal in the new role Vice President R&D.